The most important distinction
Vaccines and drugs exist against the disease caused by Ebola virus (EBOV; species Orthoebolavirus zairense, in older literature Zaire ebolavirus), but this does not mean they automatically work for Bundibugyo. The FDA explicitly warns that medical countermeasures approved or authorised for Ebola virus cannot be transferred directly to epidemics caused by other ebolaviruses.
The joint WHO and Africa CDC plan published on 5 June 2026 stated that there were no approved specific vaccines or targeted treatment for Bundibugyo virus. The WHO vaccine Q&A updated on 25 June stated at that time that WHO did not recommend using Ervebo to respond to BDBV outbreaks. A newer WHO advisory report of 7 August recommended a Phase III evaluation, and on 20 August WHO and Africa CDC announced an allocation for a trial and for health and frontline workers. This change in operational context does not make Ervebo approved or proven effective against BDBV. On 2 July, WHO announced enrolment in the PARTNERS trial evaluating MBP134 and remdesivir alone and in combination; this remains clinical evaluation, not approved, routinely available treatment.
On 24 August, Nature Medicine published the peer-reviewed accepted manuscript of a case report on a 39-year-old health worker infected in Ituri and treated after medical evacuation to Berlin. The patient received investigational MBP134 antibodies under an FDA emergency investigational new drug authorisation, remdesivir and supportive care; he recovered and was discharged on day 22. This is a single case report, and the manuscript will still undergo editorial changes before the final version. The outcome does not establish efficacy, safety in a larger population or approval; the authors themselves call for larger studies.
The media shorthand “Ebola drugs” is risky in this situation. Inmazeb and Ebanga have a regulatory basis for the disease caused by Ebola virus, that is EBOV / Orthoebolavirus zairense. For Bundibugyo virus, this is so far the candidate use of selected antibodies or antivirals in clinical trials, not the adoption of an approved treatment for a different ebolavirus.
What exists for the individual ebolaviruses
| Virus / situation | Vaccines | Treatment | How to read it for 2026 |
|---|---|---|---|
| Ebola virus (EBOV; species Orthoebolavirus zairense) | Ervebo is a licensed vaccine for the prevention of the disease caused by Ebola virus. In Europe there is also the two-dose preventive regimen Zabdeno/Mvabea. | Inmazeb and Ebanga are monoclonal antibodies registered for the treatment of infection with Ebola virus / Orthoebolavirus zairense. | These successes explain why Ebola is talked about differently today than in 2014, but they are not a direct solution for Bundibugyo. |
| Sudan virus | There is no routinely used licensed vaccine with a role analogous to Ervebo. | Medical countermeasures for Ebola virus cannot be adopted automatically; candidate products are evaluated against the specific virus. | A good example of why the word “Ebola” is not enough and the specific virus must be stated. |
| Bundibugyo virus (BDBV) | No approved specific vaccine. ChAdOx1 BDBV entered a Phase I trial on 24 July; Moderna announced vaccination of the first participants in a Canadian Phase I trial of mRNA-1469 on 4 August. | No approved targeted treatment or post-exposure prophylaxis. On 2 July, WHO announced enrolment in the PARTNERS trial of MBP134 and remdesivir in confirmed cases. On 14 July, the EBO-PEP trial of obeldesivir in selected asymptomatic direct contacts was launched. | The current 2026 outbreak rests mainly on classic public-health measures and supportive care; candidate products belong in clinical trials. |
| Taï Forest, Reston, Bombali | No practical role for the current outbreak. | No practical role for the current outbreak. | Important mainly for taxonomy, the zoonotic context and for communicating that there is more than one ebolavirus. |
Sources: FDA: Ebola medical countermeasures, FDA: Ervebo, WHO: Ebola vaccines Q&A, 25 June 2026, WHO: candidate treatments and vaccines for Bundibugyo, 28 May 2026, WHO DON607, 13 June 2026, WHO Director-General briefing, 24 June 2026, DRC INSP: PANTHER study, 29 June 2026, WHO: PARTNERS trial enrolment, 2 July 2026, WHO TAG-TP: immunomodulators and host-directed therapies, 26 June 2026, WHO / Africa CDC: continental response plan, 5 June 2026.
What WHO ranks among its priorities for Bundibugyo 2026
| Candidate | Type | Role according to WHO | Public wording |
|---|---|---|---|
| MBP134 | Monoclonal antibody | On 28 May, WHO prioritised it for clinical trials in confirmed cases of BVD; on 2 July, WHO announced enrolment in the PARTNERS trial, which evaluates MBP134 alone and in combination with remdesivir. | A candidate, not an approved treatment. |
| Maftivimab (REGN3479) | Monoclonal antibody; REGN3479 is the development code for maftivimab | On 28 May, WHO listed maftivimab in the broader prioritisation; WHO DON607 of 13 June uses the designation REGN3479 and names it alongside MBP134 in the planned clinical trial for treatment. The most recent public WHO briefing of 24 June already names MBP134 and remdesivir for the immediate trial. | A candidate for BVD, not a routinely available drug; do not automatically equate it with the approved Inmazeb combination for EBOV. |
| Remdesivir | Antiviral | On 28 May, WHO listed it in the broader prioritisation for clinical evaluation; on 2 July, WHO listed it in the PARTNERS trial alone or in combination with MBP134. | A candidate in clinical evaluation, not an approved therapy for BVD. |
| Obeldesivir | Oral antiviral | The EBO-PEP trial began on 14 July. Obeldesivir is to be evaluated as post-exposure prophylaxis in asymptomatic adults and children older than 12 who had direct contact with a confirmed case during the preceding five days. Nearly 1,000 participants are planned in the DRC and Uganda. | An investigational candidate, not approved or proven effective prophylaxis. The trial depends on rapid contact tracing; a planned remdesivir subprotocol for some younger children and pregnant or breastfeeding people is not routine care. |
| rVSV Bundibugyo | Research vaccine | WHO states probably 7–9 months to readiness for a clinical efficacy evaluation. | Vaccination for the public is not available. |
| ChAdOx1 BDBV | Research vaccine | On 24 July, Oxford announced that the first volunteer had received the candidate vaccine in the first Phase I trial in humans. The trial is planned to enrol 50 healthy adults aged 18–55 and assesses safety and immune response. | Not an approved vaccine. First administration in a Phase I trial does not demonstrate efficacy and is not public vaccination. |
| mRNA-1469 | Investigational mRNA vaccine | On 4 August, Moderna announced first vaccinations in a Canadian Phase I trial. Registry NCT07737717 has an estimated enrolment of 84 healthy adults aged 18–65 and evaluates safety, reactogenicity and immune response; since 11 August it has listed the study as recruiting, with the Truro site recruiting and two other Canadian sites not yet recruiting. | Not an approved or proven effective vaccine. Phase I recruitment is not public vaccination. |
| Ervebo | Licensed vaccine for Ebola virus (EBOV) | On 20 August, WHO and Africa CDC announced an allocation of 70,000 doses to the DRC: 20,000 for a Phase III trial and 50,000 for health and frontline workers under SAGE recommendations. | Whether Ervebo protects humans against BDBV is unknown. WHO says information and informed consent are essential; the allocation is not approval or proof of efficacy against BDBV. |
CEPI states that approximately 620,000 doses of the candidate vaccine are stockpiled for possible future investigational use and that 4,000 investigational doses were supplied for the Phase I study. These stocks must not be described as an available or approved vaccine; the product remains an investigational candidate. Oxford is preparing further studies with partners in Uganda, but their start is subject to regulatory approval and Phase I results.
On 14 July, WHO published a target product profile for future vaccines against disease caused by Bundibugyo virus. It sets minimum and preferred parameters for further development, including target populations, safety, efficacy, dosing, storage and manufacturing. It is not approval of a specific vaccine or evidence of efficacy.
The mRNA-1469 announcement marks the start of a second concurrently running BDBV candidate-vaccine trial in humans. On 18 August, the WHO Director-General summarised that two vaccines designed specifically for BDBV had entered human trials. Phase I does not, however, measure effectiveness against disease in the population, and the candidates are not part of routine response operations in the DRC or Uganda.
On 20 August, WHO and Africa CDC announced the immediate initial allocation of 70,000 Ervebo doses to the DRC. Of these, 20,000 are for a Phase III trial and 50,000 for health and frontline workers under SAGE recommendations. WHO explicitly states that whether Ervebo protects humans against BDBV is unknown; early laboratory and animal data only suggest possible protection. People offered the vaccine in or outside the trial are to receive information about risks, possible benefits and limitations and give informed consent. The allocation is not a regulatory change or proof of efficacy against BDBV.
The WHO TAG-CVP report published on 7 August summarises its 31 July meeting. With one member dissenting, the group recommended prioritising Ervebo for a Phase III BDBV trial and considered a preceding Phase II unnecessary. It also cautioned that some of the evidence is preliminary, unpublished and non-peer-reviewed, and that any efficacy against symptomatic disease and transmission might not be high.
New expert source: Nature Medicine: A case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir, peer-reviewed accepted manuscript, 24 August 2026.
New sources: WHO TAG-CVP: evidence for use of Ervebo against BDBV, published 7 August 2026, INRB / ANRS MIE–Inserm / ALIMA: EBO-PEP launch, 14 July 2026, WHO: target product profile for future BDBV vaccines, 14 July 2026, University of Oxford: first volunteer vaccinated with ChAdOx1 BDBV candidate, 24 July 2026, ISRCTN72157798: BD-Ebov-01 trial registry, Moderna: first participants in the mRNA-1469 trial, 4 August 2026, ClinicalTrials.gov NCT07737717, Nature News Q&A: interview on candidate-vaccine development, 28 July 2026, CEPI: trial launch and investigational-dose status, 13 July 2026 and UK Health Research Authority: regulatory review, 13 July 2026. At the 26 August registry check, the mRNA-1469 study remained recruiting, with the Truro site recruiting and the Halifax and Toronto sites not yet recruiting.
Preclinical directions outside the current response
In May 2026, PNAS published a preclinical study of a multivalent mRNA vaccine against orthoebolaviruses. The candidate designated [GPs+NP]@LNP encodes the glycoproteins of the Ebola, Bundibugyo and Sudan viruses and the nucleoprotein of Ebola virus; the authors describe protection in experimental animal models. This is a research direction for broader protection against ebolaviruses, not a licensed vaccine, a clinically validated product, or a tool available for the current response in the DRC and Uganda.
On 16 June, Nature Biotechnology highlighted this work as a “Broad-spectrum Ebola vaccine”. For a public text, however, it is crucial to keep to the regulatory and clinical status: this is preclinical work, and it is not certain whether and when the candidate will be tested in humans. We therefore do not rank it among the usable vaccines for 2026, nor among the WHO candidates prioritised for immediate clinical evaluation in this response.
Emerging Infectious Diseases also published a preclinical study of serum samples collected from ferrets after immunisation with an Ebola virus vaccine; the authors described limited cross-reactive antibody activity against BDBV. This is laboratory research, not evidence of human effectiveness and not a change in WHO's recommendation on Ervebo use during BDBV outbreaks.
Sources: Zhang et al., PNAS 2026, PubMed PMID 42150061, Nature Biotechnology, 16 June 2026, Emerging Infectious Diseases, 2026.
What remains the basis of care
In all diseases caused by ebolaviruses, rapid isolation, intensive supportive care, rehydration, correction of electrolytes, treatment of shock, oxygenation, organ support, treatment of secondary infections and protection of health workers are essential. Even where specific antibodies or vaccines exist, they do not replace contact tracing, safe burials and community trust.
On 11 June, WHO published clinical recommendations for filovirus diseases including the diseases caused by the Ebola, Sudan, Bundibugyo, Taï Forest and Marburg viruses; a summary followed on 15 June, and on 17 June WHO issued a public release on the recommendations. For a public text it is important to read them as support for systematic clinical monitoring, fluid therapy, treatment of shock, organ support, infection prevention and control and survivor follow-up, not as an announcement of an approved specific treatment for BVD.
For 24 June, WHO EPI-WIN scheduled a separate expert webinar on safe and scalable care for the disease caused by Bundibugyo virus in the DRC, including the running of treatment centres, clinical recommendations and care design. We take it as operational and clinical context, not as a new update of case and death counts nor as an announcement of an approved specific therapy.
In its release of 17 June, WHO explicitly stresses that, in the absence of licensed vaccines and treatment for the diseases caused by the Marburg, Bundibugyo and Sudan viruses, early supportive care improves survival. On 2 July, WHO reported that patient enrolment had begun in the PARTNERS trial evaluating MBP134 and remdesivir; on 18 August, the WHO Director-General added that the trial had enrolled 100 patients. This is an enrolment count, not an efficacy result. The WHO TAG-TP statement of 26 June at the same time cautions against simply transferring immunomodulatory experience from EBOV to BDBV without patient data. For Bundibugyo, therefore, the correct wording remains “optimised supportive care and research candidates in clinical evaluation”, not “approved treatment”.
In the confirmed Berlin patient, Charité described combined antiviral and supportive treatment with a regression of symptoms and negative follow-up PCR tests. This single clinical course, however, does not mean that an approved specific treatment for the disease caused by Bundibugyo virus exists.
Sources: WHO Ebola disease fact sheet, WHO clinical recommendations for filovirus diseases, 11 June 2026, WHO brief summary of clinical recommendations, 15 June 2026, WHO news release on the clinical recommendations, 17 June 2026, WHO EPI-WIN webinar, 24 June 2026, WHO: PARTNERS trial enrolment, 2 July 2026, WHO TAG-TP: immunomodulators and host-directed therapies, 26 June 2026, WHO emergency guidance on Ervebo during BVD outbreaks, FDA: Ebola, Charité: discharge from the special isolation unit, 6 June 2026.